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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To determine the comparative efficacy and safety of oral versus inhaled antibiotics in the treatment of adults and children with non-
cystic fibrosis bronchiectasis.
B A C K G R O U N D
Description of the condition
Bronchiectasis is a chronic inflammatory lung disease that presents
with cough, sputum production and recurrent respiratory tract in-
fections (Pasteur 2010). It is defined radiologically by the presence
of permanently dilated airways usually visualised on computed to-
mography (CT). Bronchiectasis represents a final common path-
way of multiple disorders with the most common associations be-
ing with severe infections (pneumonia, childhood infection and
Mycobacterial infection), allergic bronchopulmonary aspergillosis,
rheumatological diseases, inflammatory bowel disease and disor-
ders of mucociliary clearance such as primary ciliary dyskinesia
(Lonni 2015). Treatments for bronchiectasis have historically been
extrapolated from cystic fibrosis with a focus on antibiotic treat-
ments and physiotherapy (Chalmers 2016).
Although it has previously been considered a relatively rare disease
(Kolbe 1996), bronchiectasis is increasing, with higher rates in de-
veloping countries, women and those aged over 60 years (Chang
2003;Weycker 2005; Habesoglu 2011; Seitz 2012). Global preva-
lence rates vary, with estimates of 0.5 in Finland and 3.7 in New
Zealand per 100,000 though some of these data are more than 10
years old (European Lung White Book 2013). Recent data sug-
gest that incidence and prevalence in the UK may be higher than
previously estimated (Quint 2016). Over a 9-year period to 2013,
point prevalence rates increased by over 60% to 566 in women
and 485 in men per 100,000, with approximately 263,000 adults
living with bronchiectasis in 2013. Similarly, the rate of new cases
rose by 63% to 35 per 100,000 in women and 27 per 100,000
in men, with over 15,000 new cases in 2013. However, higher
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prevalence rates may be due to the increasing use of CT scanning
and a greater awareness of the disease (Goeminne 2016).
Mortality rates in England andWales rose by 3% per year between
2001 to 2007 (Roberts 2010), and hospitalisations also increased
by 3%per year over a 9-year period in theUS (Seitz 2010). Average
mortality rates in Europe are estimated at 0.3 per 100,000 general
population in 27 of the 28 EU countries (ranging from 0.01 in
Germany to 1.18 in the UK) and 0.2 per 100,000 in 9 non-EU
countries (ranging from 0.01 in Azerbaijan to 0.67 in Kyrgyzstan),
based on 2005 to 2009 data (European Lung White Book 2013).
Quint reported higher age-adjusted mortality rates for the UK,
with estimates 2.26 times higher in women and 2.14 times higher
in men compared to the general population (Quint 2016).
Description of the intervention
Bronchiectasis is characterised by a common pathophysiological
pathway that consists of a vicious cycle. Three elements play a
pivotal role in this cycle: inflammation, infection and airway dam-
age by enzymatic components. In this cycle, infection or colonisa-
tion by various micro-organisms cause an inflammatory response.
When this inflammation is not able to clear the micro-organism,
the inflammation can become chronic and even excessive com-
pared to the bacterial burden. This can then finally result in airway
damage and remodelling (Goeminne 2010).
Interventions aiming to reduce or break this vicious cycle often
focus on the treatment of the chronic bacterial infection. Data
show that these chronic infections are most often caused by Gram-
negatives, with a special focus on Pseudomonas aeruginosa as this
has been linked with more severe disease and increased morbidity
and mortality (Wilson 2016). To treat or eradicate these chronic
infections, long courses and high dosage of systemic antibiotic
treatment are often required. This is frequently accompanied by
side effects and can also result in resistance. Therefore, inhaled
antibiotics are increasingly being considered, as they can deliver
high concentrations of the antibiotic at the site of infection with
less systemic absorption and toxicity, but can result in increased
airway irritation or bronchospasm (Geller 2009).
How the intervention might work
A recent Cochrane review of 18 trials in patients with bronchiecta-
sis receiving prolonged antibiotics, showed that there was a signif-
icant reduction of exacerbation risk (Hnin 2015). Furthermore,
recent data clearly suggest an important relationship between in-
flammation and bacterial load/presence in bronchiectasis. Chronic
Pseudomonas aeruginosa infection was associated with increased
matrix metalloprotease activity and a higher bacterial load was
associated with an increase in hospitalisations, exacerbations and
symptom severity (Chalmers 2012;Goeminne 2014). Chalmers et
al. also showed that both short- and long-term antibiotic treatment
significantly reduced airway and systemic inflammation. This is
in line with a series of long-term systemic antibiotic therapy tri-
als with macrolides, proving that long-term oral macrolides are
useful for patients with bronchiectasis in reducing exacerbations
and improving clinical symptoms (Wong 2012; Altenburg 2013;
Serisier 2013). It is speculated thatmacrolides not only act through
their antibacterial activity but also have anti-inflammatory and
immunomodulatory effect (Altenburg 2011a). These long-term
oral macrolide treatments, however, raise some concerns as to sa-
fety and bacterial resistance (Altenburg 2011b). Inhaled antibi-
otics may provide an effective suppressive antibiotic therapy with
an acceptable safety profile in adult patients with stable non-cys-
tic fibrosis (CF) bronchiectasis and chronic bronchial infection.
Their use has been widespread in CF since the early 1990s, as in-
haled antibiotics improve lung function and reduce exacerbation
rates (Ryan 2011). For inhaled antibiotics, different antibiotic reg-
imens have been investigated in non-CF bronchiectasis, including
inhaled amikacin, aztreonam, ciprofloxacin, gentamicin, colistin
and tobramycin. The antibiotics chosen often have a concentra-
tion-dependent effect, where an increased greater area under the
curve/minimum inhibitory concentration ratio improves bacterial
killing (Restrepo 2015). As resistance is one of the concerns in
chronic antibiotic treatment, these inhaled antibiotics may achieve
very high concentrations of the drug in the airways, overcom-
ing bacterial resistance (Dudley 2008; Rubin 2008; Quon 2014).
On the other hand, inhalation antibiotic treatment is hampered
by a delivery that is not uniform, creating a concentration gradi-
ent with lower concentrations in deeper parts of the lung (Rubin
2008). In non-CF bronchiectasis, a recent review found that long-
term inhaled antibiotics can effectively reduce the sputum bacte-
rial density, increase Pseudomonas aeruginosa eradication and at-
tenuate the risk of exacerbation, but with higher risk of wheeze
and bronchospasm (Yang 2015).
Why it is important to do this review
In meta-analyses of trials involving participants with non-CF
bronchiectasis, authors have concluded that inhaled antibiotics re-
duced sputum bacterial load and the risk of acute exacerbation,
with an acceptable safety profile, when compared to symptomatic
treatment or placebo (Brodt 2014; Yang 2015). However, in real-
ity, clinicians will often be faced with the choice between various
routes of delivering antibiotics, not only the choice whether or not
to give them. A comparison between the oral and inhaled route
was highlighted as a priority in a recently published overview of
interventions for bronchiectasis (Welsh 2015).The potential bene-
fits of improved bacterial killing and reduced risk of bacterial resis-
tance described above need to be weighed against the cost of drug
delivery via inhalation and specific side effects associated with this
route, such as bronchospasm and wheeze (BNF (online); Brodt
2014; Yang 2015).
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Therefore in this review we will include studies that directly com-
pare the effectiveness and safety of delivering antibiotics by in-
halation or orally, both in an acute setting and for longer-term
prophylaxis. We intend to summarise the evidence to provide the
most up-to-date information for guideline developers, clinicians
and patients, and highlight future research needs. This review is
being conducted alongside four other closely related Cochrane re-
views: Macrolide antibiotics for non-cystic fibrosis bronchiectasis
(Kelly 2016); Dual antibiotics for non-cystic fibrosis bronchiecta-
sis (Felix 2017a); Head to head trials of antibiotics for non-cystic
fibrosis bronchiectasis (Kaehne 2017); and Continuous versus in-
termittent antibiotics for bronchiectasis (Felix 2017b).
O B J E C T I V E S
To determine the comparative efficacy and safety of oral versus
inhaled antibiotics in the treatment of adults and children with
non-cystic fibrosis bronchiectasis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs). We will in-
clude studies reported as full-text, those published as abstract only,
and unpublished data.
Types of participants
We will include adult and child participants diagnosed with
bronchiectasis by bronchography, plain film chest radiograph, or
high-resolution computed tomography. Studies will be excluded
if patients have been receiving continuous or high-dose antibiotics
immediately before the study, or if they have received a diagnosis of
cystic fibrosis (CF), sarcoidosis, active allergic bronchopulmonary
aspergillosis or active non-tuberculous Mycobacterial infection.
Types of interventions
We will include studies comparing oral antibiotics with inhaled
antibiotics. Short-term use (< 4 weeks) for treating acute exacer-
bations and longer-term use as a prophylactic (≥ 4 weeks) will
be considered separately. We will consider intraclass as well as in-
terclass comparisons. We will include the following comparison
groups.
1. Inhaled aminoglycosides versus oral antibiotics
2. Inhaled polymyxin versus oral antibiotics
3. Inhaled beta-lactam versus oral antibiotics
Types of outcome measures
Primary outcomes
We will include the following primary outcomes for short-term
therapy, longer-term therapy or both, as indicated.
1. Duration of exacerbation (short-term)
2. Exacerbation (both), e.g. frequency during follow-up or
time to first exacerbation
3. Hospitalisations due to exacerbations (both)
4. Serious adverse events (both)
Secondary outcomes
1. Response rates as defined by study authors (e.g. diary cards
of physician global assessment)
2. Sputum volume and purulence
3. Measures of lung function (e.g. forced expiratory volume in
one second (FEV1))
4. Adverse events (e.g. cardiac arrhythmias, gastrointestinal
symptoms, hearing impairment, bronchospasm)
5. Mortality
6. Emergence of resistance to antibiotics or treatment
emergent pathogens
7. Exercise capacity (e.g. Six-Minute Walk Test (6MWT))
8. Quality of life (QOL) (e.g. St George Respiratory
Questionnaire (SGRQ) or alternative QOL tools)
9. Eradication of pathogens
Reporting one or more of the outcomes listed here in the study is
not an inclusion criterion for the review.
We will include the above secondary outcomes for both short-
term and long-term therapy.
Search methods for identification of studies
Electronic searches
We will identify studies from the Cochrane Airways Group’s Spe-
cialised Register (CAGR), which is maintained by the Information
Specialist for the Group. The Register contains trial reports iden-
tified through systematic searches of bibliographic databases in-
cluding theCochrane Central Register of Controlled Trials (CEN-
TRAL),MEDLINE, Embase, CINAHL, AMED, and PsycINFO,
and handsearching of respiratory journals and meeting abstracts
(please see Appendix 1 for further details). We will search all
records in the CAGR using the search strategy in Appendix 2.
3Oral versus inhaled antibiotics for non-cystic fibrosis bronchiectasis (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
We will also conduct a search of
ClinicalTrials.gov (www.ClinicalTrials.gov) and the WHO trials
portal (www.who.int/ictrp/en/). We will search all databases from
their inception to the present, and we will impose no restriction
on language of publication.
Searching other resources
We will check the reference lists of all primary studies and review
articles for additional references.We will search relevant manufac-
turers’ websites for study information.
We will search for errata or retractions from included studies pub-
lished in full text on PubMed and report the date this was done
within the review.
Data collection and analysis
Selection of studies
Two review authors (PG and LF) will screen the titles and abstracts
of the search results independently and code them as ’retrieve’
(eligible or potentially eligible/unclear) or ’do not retrieve’.We will
retrieve the full-text study reports of all potentially eligible studies
and two review authors (PG and LF) will independently screen
them for inclusion, recording the reasons for exclusion of ineligible
studies. We will resolve any disagreement through discussion or, if
required, we will consult a third person/review author (SS/SJM).
Wewill identify and exclude duplicates and collatemultiple reports
of the same study so that each study, rather than each report, is
the unit of interest in the review. We will record the selection
process in sufficient detail to complete a PRISMA flow diagram
and ’Characteristics of excluded studies’ table (Moher 2009).
Data extraction and management
We will use a data collection form for study characteristics and
outcome data, which has been piloted on at least one study in the
review. One review author (LF) will extract the following study
characteristics from included studies.
1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and location, study
setting, withdrawals and date of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications and excluded medications.
4. Outcomes: baseline exacerbation data (e.g. frequency,
duration), primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for studies and notable conflicts of interest
of trial authors.
Two review authors (RN and LF) will independently extract out-
come data from included studies. We will note in the ’Character-
istics of included studies’ table if outcome data were not reported
in a usable way. We will resolve disagreements by consensus or by
involving a third person/review author (SS/SJM). One review au-
thor (LF) will transfer data into the ReviewManager file (RevMan
2014). We will double-check that data are entered correctly by
comparing the data presented in the systematic review with the
study reports. A second review author (SS) will spot-check study
characteristics for accuracy against the study report.
Assessment of risk of bias in included studies
Two review authors (RN and LF) will assess risk of bias indepen-
dently for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve any disagreements by discussion or by involving
another author (SS/SJM). We will assess the risk of bias according
to the following domains:
1. random sequence generation;
2. allocation concealment;
3. blinding of participants and personnel;
4. blinding of outcome assessment;
5. incomplete outcome data;
6. selective outcome reporting; and
7. other bias.
We will judge each potential source of bias as high, low or unclear
risk, and provide a quote from the study report together with a
justification for our judgement in the ’Risk of bias’ table. We will
summarise the ’Risk of bias’ judgements across different studies for
each of the domains listed.Wewill consider blinding separately for
different key outcomes where necessary (e.g. for unblinded out-
come assessment, risk of bias for all-cause mortality may be very
different than for a patient-reported pain scale). Where informa-
tion on risk of bias relates to unpublished data or correspondence
with a trialist, we will note this in the ’Risk of bias’ table.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
Assessment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and justify any deviations from it in the ’Differences between
protocol and review’ section of the systematic review.
Measures of treatment effect
We will analyse dichotomous data as odds ratios (ORs) and con-
tinuous data as mean differences (MDs) or standardised mean
differences (SMDs). We will enter data presented as a scale (e.g.
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quality of life measures) with a consistent direction of effect. We
will describe skewed data narratively (for example, as medians and
interquartile ranges for each group).
We will undertake meta-analyses only where this is meaningful;
that is, if the treatments, participants and the underlying clinical
question are similar enough for pooling to make sense.
Where multiple trial arms are reported in a single study, we will
include only the relevant arms. If two comparisons (e.g. drug A
versus placebo and drug B versus placebo) are combined in the
samemeta-analysis, wewill either combine the active arms or halve
the control group to avoid double-counting.
If adjusted analyses are available (ANOVA or ANCOVA) we will
use these as a preference in our meta-analyses. If both change from
baseline and endpoint scores are available for continuous data, we
will use change from baseline scores unless there is low correlation
between measurements in individuals. If a study reports outcomes
at multiple time points (repeated observations), we will perform
separate analyse for different periods of follow-up.
We will use intention-to-treat (ITT) analyses where they are re-
ported (i.e. all those who were randomised are analysed) instead
of completer or per protocol analyses.
Unit of analysis issues
For dichotomous outcomes, we will use participants, rather than
events, as the unit of analysis (i.e. number of children admitted to
hospital, rather than number of admissions per child). However,
if rate ratios are reported in a study, we will analyse them on this
basis. We will only meta-analyse data from cluster-RCTs if the
available data have been adjusted (or can be adjusted), to account
for the clustering.
Dealing with missing data
We will contact investigators or study sponsors in order to verify
key study characteristics and obtain missing numerical outcome
data where possible (e.g. when a study is identified as an abstract
only). Where this is not possible, and the missing data are thought
to introduce serious bias, we will take this into consideration in
the GRADE rating for affected outcomes.
Assessment of heterogeneity
We will use the I² statistic to measure heterogeneity among the
studies in each analysis. If we identify substantial heterogeneity
we will report it and explore the possible causes by prespecified
subgroup analysis.
Assessment of reporting biases
If we are able to pool more than 10 studies, we will create and
examine a funnel plot to explore possible small study and publi-
cation biases.
Data synthesis
We will use a random-effects model and perform a sensitivity
analysis with a fixed-effect model.
’Summary of findings’ table
We will create a ’Summary of findings’ table using the follow-
ing outcomes: duration of exacerbations, exacerbations (frequency
and time to first exacerbation), frequency of hospitalisations due
to exacerbations, serious adverse events, response rates, mortality
and quality of life. We will use the five GRADE considerations
(risk of bias, consistency of effect, imprecision, indirectness and
publication bias) to assess the quality of a body of evidence as it
relates to the studies that contribute data for the prespecified out-
comes. We will use the methods and recommendations described
in Section 8.5 and Chapter 12 of the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011), using GRADE-
pro software (GRADEpro GDT). We will justify all decisions to
downgrade the quality of studies using footnotes and we will make
comments to aid the reader’s understanding of the review where
necessary.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses.
1. Adults versus children (18 years or younger)
2. Patients chronically infected with Pseudomonas aeruginosa
versus those not infected with Pseudomonas aeruginosa
3. Macrolide versus non-macrolide oral antibiotic
We will use the following outcomes in subgroup analyses.
1. Exacerbation duration (short-term therapy)
2. Exacerbation, e.g. frequency during follow-up or time to
first exacerbation
3. Hospitalisation due to exacerbations
4. Adverse events
We will use the formal test for subgroup interactions in Review
Manager (RevMan 2014).
Sensitivity analysis
We plan to carry out the following sensitivity analyses, removing
the studies judged as high risk of bias from the primary outcome
analyses.
1. Exacerbation duration (short-term therapy)
2. Exacerbation, e.g. frequency during follow-up or time to
first exacerbation (both)
3. Hospitalisation due to exacerbations
4. Adverse events
We will compare the results from a fixed-effect model with the
random-effects model.
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group’s Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL (The Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
Embase (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
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Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
Bronchiectasis search
1. exp Bronchiectasis/
2. bronchiect$.mp.
3. bronchoect$.mp.
4. kartagener$.mp.
5. (ciliary adj3 dyskinesia).mp.
6. (bronchial$ adj3 dilat$).mp.
7. or/1-6
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
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Appendix 2. Search strategy to identify relevant studies from the CAGR
#1 BRONCH:MISC1
#2 MeSH DESCRIPTOR Bronchiectasis Explode All
#3 bronchiect*
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Anti-Bacterial Agents Explode 1
#6 antibiotic* or anti-biotic*
#7 anti-bacteri* or antibacteri*
#8 *cillin
#9 *mycin OR *micin
#10 *oxacin
#11 *tetracycline
#12 macrolide*
#13 quinolone*
#14 trimethoprim
#15 ceph*
#16 sulpha*
#17 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16
#18 #4 and #17
Note: in search line #1, MISC1 denotes the field in the record where the reference has been coded for condition, in this case, bronchiectasis.
C O N T R I B U T I O N S O F A U T H O R S
All review authors contributed to the Background section. SJM and SS contributed to the Methods section.
PG and LF will independently screen titles and abstracts for inclusion of all the studies we identify as a result of the search and code
them as ’retrieve’ (eligible or potentially eligible/unclear) or ’do not retrieve’. We will retrieve the full-text study reports/publication.
PCG and LF will independently screen the full-text and identify studies for inclusion, and identify and record reasons for exclusion of
the ineligible studies. We will resolve any disagreement through discussion or, if required, we will consult a third review author (SS,
SJM or JDC).
RN and LF will independently assess risk of bias for each study using the criteria outlined in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). We will resolve any disagreements by discussion or by involving another review author (SS,
SJM or JDC).
LF, SS and SJM will complete the analyses and Results section. All review authors will contribute to the Discussion, Conclusions and
remaining sections of the review.
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